Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBR854 in advanced solid tumors
NCT05194709Phase 1Unknown
- Sponsor
- Wuxi People's Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Other Engineered Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IBR854 in solid tumor, sponsored by Wuxi People's Hospital. Primary endpoint: Number of Adverse Events. Status: unknown.
02
Drugs
IBR854
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05194709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05194709.